Prism Medico & Pharmacy Limited has submitted its mandatory annual disclosure under SEBI regulations, confirming that no promoter share encumbrances occurred during the financial year ended 31st March, 2026. The disclosure was filed with stock exchanges on 07.04.2026 as required under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Regulatory Compliance Details

The company filed identical disclosures with both BSE Limited and Metropolitan Stock Exchange of India Limited (MSEI), confirming compliance with substantial acquisition disclosure requirements. Director Davender Singh (DIN: 09447213) signed the company's submission to exchanges.

Promoter Confirmation

Symbiosis Pharmaceuticals Private Limited, acting as a promoter entity, provided written confirmation that no encumbrances were made on shares held by promoters and persons acting in concert during FY26. The confirmation was signed by authorized signatory Mr. Jagbir Singh on behalf of the promoter group.

Stock Exchange Submissions

The disclosures were submitted to both exchanges where the company's shares are listed:

Company Information

Prism Medico and Pharmacy Limited operates from its registered office at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030. The company maintains investor grievance communication through investorgrievancewmcl@gmail.com and continues to fulfill its regulatory disclosure obligations as a listed entity.

The annual disclosure represents standard compliance practice for listed companies, ensuring transparency regarding promoter shareholding patterns and any potential encumbrances that could affect shareholder interests.

Prism Medico & Pharmacy Limited has submitted a regulatory filing to stock exchanges confirming that it has not issued any non-convertible securities during the fourth quarter of fiscal year 2026. The intimation, dated 06/04/2026, was filed under Regulation 57(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance Filing

The company addressed its communication to both BSE Limited and Metropolitan Stock Exchange of India Limited (MSEI), where its shares are listed. The filing serves as a mandatory disclosure requirement under SEBI LODR regulations for companies regarding their non-convertible securities status.

Company Information and Authorization

Prism Medico and Pharmacy Limited, incorporated under CIN L24100HP2002PLC009299, has its registered office located at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030. The regulatory filing was authorized and signed by Davender Singh, Director of the company, holding DIN 09447213.

No Payment Obligations During Q4FY26

Since the company has not issued any non-convertible securities, it confirms that there were no interest, dividend, or principal payment obligations due during the quarter from 01st January, 2026 to 31st March, 2026. This confirmation is part of the company's ongoing compliance with regulatory disclosure requirements.

The filing represents routine regulatory compliance by the company to keep stock exchanges and investors informed about its securities status and related payment obligations.